News

What’s Happening With HIMS Stock?
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Hims Reaffirms 2025 Sales Guidance After Posting Quarterly Beat
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
Fierce Healthcare16h
Hims & Hers' Q1 revenue doubles to $586M, boosted by growth in weight loss business
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
Imitation weight-loss drugs boosted Hims & Hers. Executives cashed in.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
24/7 Wall St. on MSN15h
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Up 30% In A Week, HIMS Stock Is Just Getting Warmed Up
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Nader ...
Novo Nordisk teams with telehealth firms Hims, Ro to sell Wegovy at lower price
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, Constellation Energy, Clorox, Hims & Hers, Neurocrine, AMD, and More
Palantir Technologies raises its full-year outlook but the stock falls, while Ford suspends guidance because of uncertainty ...